Clinical Trials Logo

Filter by:
NCT ID: NCT01833065 Terminated - Clinical trials for Chronic Idiopathic Constipation

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Start date: April 2013
Phase: Phase 3
Study type: Interventional

12 Week Efficacy and Safety Trial Followed by a 4 Week Withdrawal Period for Patients with Chronic Idiopathic Constipation.

NCT ID: NCT01831193 Completed - Proteinuria Clinical Trials

Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease

Start date: February 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.

NCT ID: NCT01830543 Completed - Atrial Fibrillation Clinical Trials

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

PIONEER AF-PCI
Start date: May 10, 2013
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or prasugrel or ticagrelor).

NCT ID: NCT01829295 Completed - Uveitis Clinical Trials

Methotrexate and Mycophenolate Mofetil for UVEITIS

FAST
Start date: August 2013
Phase: Phase 3
Study type: Interventional

In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative effectiveness trial.

NCT ID: NCT01829009 Withdrawn - Sarcopenia Clinical Trials

Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women

Start date: n/a
Phase: N/A
Study type: Interventional

Aging is characterized by a progressive loss of multiple physical and cognitive abilities. From these changes, the most important one is the loss of muscle mass, which has been called "sarcopenia". Resistance exercise is a therapeutic approach for sarcopenia, nevertheless there is no universal consensus. Therefore, this research is interested in determining the effect of a resistance exercise program on physical performance and/or functional status in sarcopenic older women. The main study hypothesis is that a program of resistance exercise will improve physical performance and functional status in sarcopenic older women compared against general recommendations. This is a single-blind, controlled clinical trial, including women> 70 years, living in the community with sarcopenia. Those who agree to participate, will be randomly assigned to one of the following groups: 1. Resistance Exercise Group 2. General Recommendations Group (control) The study will last 24 weeks, with 4 measurements performed at baseline, week 6, 12 and 24. Multilevel models (random effects) will be constructed for the comparison between the two groups. Tests will be conducted with a P=0.05 and confidence intervals at 95%. This protocol has been approved by the local ethics committee.

NCT ID: NCT01828099 Completed - Clinical trials for Non-Small Cell Lung Cancer

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Start date: July 9, 2013
Phase: Phase 3
Study type: Interventional

The primary purpose of the study was to compare the antitumor activity of LDK378 versus reference chemotherapy. Patients in the chemotherapy arm were given the option to switch to LDK378 after confirmed progressive disease (PD), while also had the choice to continue with pemetrexed treatment.

NCT ID: NCT01826422 Completed - Clinical trials for Muscular Dystrophy, Duchenne

Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients

Start date: March 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of docosahexaenoic fatty acid and eicosapentaenoic fatty acid supplementation for six months on the inflammation state as well as the process of muscular regeneration and the metabolic disorders like obesity and insulin resistance in patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (DMB) compared to those receiving placebo.

NCT ID: NCT01824862 Completed - Clinical trials for Diabetic Retinopathy

Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema

Start date: January 2013
Phase: N/A
Study type: Observational [Patient Registry]

Clinically significant macular edema (CSME) is a thickening of the macula associated with the risk of visual loss, which increases its centre is involved. Functional evaluation of the macula relies on best corrected visual acuity; however, neural dysfunction in diabetic eyes appears before retinal thickening and visual loss. Retinal sensitivity decreases in eyes with CSME, but it is unknown whether it differs between eyes with and without centre thickening. Aim: To compare the reduction of foveal sensitivity in eyes with CSME, with and without centre thickening.

NCT ID: NCT01824290 Completed - Clinical trials for Hypertension, Pulmonary

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Start date: February 5, 2014
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 year extension period (Period 2) during which participants will receive tadalafil.

NCT ID: NCT01822184 Completed - Hunter Syndrome Clinical Trials

Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)

Start date: January 18, 2013
Phase:
Study type: Observational

Hunter syndrome (Mucopolysaccharidosis II, [MPS II]) is a rare, genetically linked lysosomal storage disease (LSD) caused by deficiency of the enzyme, iduronate-2-sulfatase (I2S). Most MPS II patients will present with some degree of neurodevelopmental involvement, ranging from severe cognitive impairment and behavioral problems to mildly impaired cognition. This is an observational study; no investigational treatment will be administered. The primary objective of this study is to evaluate the neurodevelopmental status of pediatric patients with MPS II over time and to gain information to guide future treatment studies in this patient population.